Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from 111 ( (YI) ) is now available.
111, Inc. announced its unaudited financial results for Q3 2025, achieving non-GAAP net profitability for the third consecutive quarter and generating positive operating cash flow. The company has transitioned to an asset-light business model, divesting self-operated subsidiaries while retaining their service capabilities as fulfillment partners. Despite a decline in revenues by 16.7% year-on-year, 111 has improved operational efficiency through its ‘MANTIANXING’ initiative, enhancing supply chain capabilities, customer count, and gross merchandise value. This strategic realignment strengthens liquidity and profitability, with plans to further leverage AI technology to build an advanced platform for pharmaceutical transactions.
The most recent analyst rating on (YI) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on 111 stock, see the YI Stock Forecast page.
Spark’s Take on YI Stock
According to Spark, TipRanks’ AI Analyst, YI is a Underperform.
The overall stock score is driven by significant financial challenges, bearish technical indicators, and poor valuation metrics. The lack of earnings call and corporate events data further limits the potential for a positive outlook.
To see Spark’s full report on YI stock, click here.
More about 111
111, Inc. is a leading tech-enabled healthcare platform based in Shanghai, China. The company focuses on digitally transforming the healthcare value chain, offering services that optimize pharmaceutical procurement and supply chain management to benefit pharmacies, suppliers, and consumers across the country.
Average Trading Volume: 14,405
Technical Sentiment Signal: Sell
Current Market Cap: $29.56M
For detailed information about YI stock, go to TipRanks’ Stock Analysis page.